Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists map bacteria in lung cancer patients to pave way for new treatments

NCT ID NCT03068663

Knowledge-focused Sponsor: Centre Jean Perrin Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at the bacteria living in the gut, lungs, and airways of 40 people with non-small cell lung cancer. Half receive surgery only, and half get chemotherapy before surgery. Researchers collect samples like blood, saliva, stool, and lung tissue to see how these bacteria change. The goal is to understand the bacteria better so future studies can test if probiotics help make cancer treatment work better or cause fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could lay the groundwork for future treatments that use probiotics or prebiotics to improve cancer therapy tolerance and effectiveness.
What could go wrong
This is a small, early exploratory study with only 40 participants, so results may not apply to all lung cancer patients. It does not test any treatment directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2017

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * non small cell lung carcinoma patient suitable for surgery, or chemotherapy followed by surgery * BMI \<29.9 kg/m² * not taking antibiotics, corticosteroids and/or immunosuppressants at least during two months before inclusion * not taking prebiotics, probiotics or symbiotics at least during two months before inclusion * signing the written consent before enrollment in the study * affiliation to the national health insurance (or system alike) according to the law from 9th August 2004 Exclusion Criteria: * cognitive difficulties * refusal of participation or inability to give a clear consent * digestive or pulmonary infection of a long duration during the two months preceding the study (with antibiotic treatment) * inflammatory digestive pathology * concurrent treatment with experimental medication, participation in another clinical therapeutic study within 30 days * presence of colostomy, total or partial gastrectomy * previous esophageal surgery * previous ORL (otho-rhino-laryngo) cancer treated by radiotherapy or surgery * patient enable to follow the requirements of the study * patient deprived of his rights by administrative or judicial decision

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer

Contacts and locations

Locations

  • Centre Jean Perrin

    Clermont-Ferrand, Puy de dôme, 63003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.